News

23andMe sale reveals what your genetic data is worth. It’s less than you think
The price tag of this acquisition suggests that the value of genetic data is declining. Back in 2018, the drug company GSK ...
Regeneron Pharmaceuticals to buy 23andMe for $256M — taking control of genetic data of millions
It will acquire genetic data of more than 15 million customers – raising privacy concerns from individuals who had willingly ...
Regeneron Continues To Regenerate Its Drug Pipeline, While Keeping Leverage Down
Regeneron earns a buy rating with strong profit margins, low debt, and growth potential. Discover why shares may see a 39% ...
23andMe was once worth $6 billion. What's left of the DNA testing startup is being bought for $256 million.
Regeneron is buying the assets of 23andMe, which filed for Chapter 11 bankruptcy in March after facing a series of hurdles ...
Yahoo Finance21d
Q1 2025 Regeneron Pharmaceuticals Inc Earnings Call
Thank you for your interest in Regeneron and welcome to our first quarter 2025 earnings conference call. An archive and transcript of this call will be available on Regeneron's Investor ...
Morningstar1mon
Regeneron Announces Investor Conference Presentations
The sessions may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays and ...
STAT5d
Amgen loses $400 million antitrust battle to Regeneron
Morning! Today we start with some breaking newss: Novo Nordisk’s CEO is stepping down. We also discuss a new, tailored CRISPR treatment for an infant with a deadly disease, how Amgen owes Regeneron ...
Fintel on MSN6d
Citigroup Upgrades Regeneron Pharmaceuticals (REGN)
Fintel reports that on May 14, 2025, Citigroup upgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN) from ...